Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Xin Yi Foong | Breast Cancer | Best Researcher Award

Published on by Oncology

Ms. Xin Yi Foong | Breast Cancer | Best Researcher Award

Core Surgical Trainee | Mid Yorkshire Teaching NHS Trust | United Kingdom

Dr Xin Yi Foong is a clinical researcher in Plastic and Reconstructive Surgery whose academic work is centred on improving the safety, accuracy, and reliability of autologous breast reconstruction through quantitative imaging and evidence-based microsurgical innovation. Her research explores the use of indocyanine green (ICG) fluorescence imaging to guide intraoperative evaluation of mastectomy flap perfusion, with particular emphasis on establishing objective perfusion scoring methods that support consistent, data-guided surgical decisions. Her published study in the Journal of Plastic, Reconstructive & Aesthetic Surgery introduced a structured quantitative perfusion algorithm that demonstrated strong discriminatory capability in identifying poorly perfused tissue and informing reconstructive planning, offering evidence that aligns with national quality frameworks and enhances postoperative outcomes. Alongside this work, she is investigating postoperative monitoring strategies in DIEP flap reconstruction, assessing early-phase observation models that preserve patient safety while promoting efficient and clinically coherent perioperative pathways. Her wider academic activity includes outcome audits, service-improvement initiatives, and reconstructive pathway analyses, all aimed at refining surgical workflows through quantitative measures, imaging-based assessment, and rigorous postoperative metrics. Conducted within multidisciplinary teams of plastic surgeons, anaesthetists, and breast specialists, her research supports the translation of imaging-derived insights into routine clinical practice. Through a growing publication profile, an active ORCID research identity, and sustained commitment to scientifically grounded surgical advancement, Dr Foong contributes to the development of reproducible, clinically meaningful, and patient-centred innovations that strengthen microsurgical dependability and elevate the overall quality of care within reconstructive breast surgery.

Profiles: Scopus | ORCID

Featured Publications

1. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does indocyanine green imaging perfusion scoring reduce mastectomy flap necrosis in immediate autologous breast reconstruction? A single-centre cohort study. Journal of Plastic, Reconstructive & Aesthetic Surgery, 111, 198–206.

2. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does intraoperative indocyanine green (ICG) reduce the outcome of mastectomy skin flap necrosis in patients undergoing immediate breast reconstruction? European Journal of Surgical Oncology. Advance online publication. 

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Rui Liu | Tumor Radiobiology | Best Researcher Award

Published on by Oncology

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Published on by Oncology

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:

  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024

    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024

    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024

    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024

    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024

Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

Published on by Oncology

Prof. Dr. Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

The First Medical Center, Chinese PLA General Hospital | China

AUTHOR PROFILE

ORCID ID

🌟YUNSHENG YANG, M.D. – A LEADER IN GASTROENTEROLOGY 🏥

🎓EARLY ACADEMIC PURSUITS 

Dr. Yunsheng Yang earned his M.D. from the First Military Medical University in 1995, laying the foundation for his illustrious medical career. He pursued postdoctoral training at the Fourth Military Medical University in China, further honing his expertise in gastroenterology. His academic journey extended internationally with visiting scholar positions at the University of Sydney’s Westmead Hospital in 2008 and Mayo Clinic Rochester in 2014, where he gained invaluable global exposure to advanced medical practices.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently, Dr. Yang serves as the Academic Director of the Department of Gastroenterology and Hepatology at the First Medical Center, Chinese PLA General Hospital (PLAGH, 301 Hospital) in Beijing, China. His leadership extends beyond national borders, with visiting or adjunct professorships at Shenzhen University, Universitas Amoiensis, and the University of Michigan, USA.

His involvement in prestigious medical societies includes being the immediate past president of the Chinese Society of Gastroenterology and the Director of the APSDE Training Center in PLAGH since 2006. Dr. Yang actively engages with the World Gastroenterology Organization (WGO), serving as a scientific committee member and having previously contributed to the WGO Endoscopy Group and Nomination Committee.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

Dr. Yang’s clinical expertise primarily revolves around gastrointestinal (GI) disorders and therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP). His research is focused on robot-assisted endoscopy and GI microbiota, where he has pioneered multiple innovative procedures in China, including:

  • Endoscopic suturing for GERD (2001)
  • Double balloon enteroscopy (2003)
  • Peroral video cholangioscopy and laser lithotripsy (2004)
  • Confocal endomicroscopy (2006)
  • MUSE for GERD (2017)
  • Fecal Microbiota Transplantation (FMT) clinical trials for IBD, autism, and Tourette syndrome (since 2014)

Notably, he led the development of the YunSRobot, a robot-assisted GI endoscopy system, successfully performing gastroscopy on human volunteers in 2017 and completing remote gastroscopy in 2021. These groundbreaking achievements have been published and indexed in PubMed.

📚IMPACT AND INFLUENCE 

Dr. Yang’s influence in the field of gastroenterology is reflected in his extensive publication record. He has authored over 200 articles in Chinese journals and more than 150 papers in international SCI-indexed journals, including prestigious titles such as Gastroenterology, Hepatology, The American Journal of Gastroenterology (AJG), Gastrointestinal Endoscopy (GIE), Alimentary Pharmacology & Therapeutics (AP&T), and Gut.

As an editorial board member for Gut and AP&T, and associate editor for MMR and JDD, he continues to shape the direction of gastroenterology research and clinical practice worldwide.

🌟ACADEMIC CITES AND RECOGNITION 

Dr. Yang’s research contributions have been extensively cited by peers in the medical and scientific communities. His innovations in endoscopic procedures and gastrointestinal microbiota research have influenced treatment protocols and technological advancements in digestive health worldwide. His pioneering work on FMT for neurological conditions and robotic-assisted endoscopy is setting new standards in precision medicine.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Dr. Yang’s enduring legacy lies in his transformative impact on gastroenterology, blending cutting-edge technology with clinical expertise. His leadership in developing robotic-assisted endoscopy has the potential to revolutionize non-invasive diagnostics and treatment, paving the way for AI-integrated endoscopic procedures.

Looking ahead, Dr. Yang continues to push the boundaries of GI research, particularly in the integration of robotics, microbiota-based therapies, and novel endoscopic interventions. His mentorship of young gastroenterologists ensures a lasting impact on the field, fostering the next generation of leaders in digestive health research and clinical innovation.

🌍CONCLUSION 

Dr. Yunsheng Yang stands as a trailblazer in the field of gastroenterology, with his extensive contributions in clinical practice, research, and technological innovation. His groundbreaking advancements in robot-assisted endoscopy and GI microbiota research have set new benchmarks in the medical field. His dedication to patient care, scientific discovery, and mentorship ensures his influence will resonate for years to come, shaping the future of digestive health worldwide.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.
    Authors: Yan J, Chen H, Zhang Y, Peng L, Wang Z, Lan X, Yu S, Yang Y.
    Year: 2024

 

  1. Title: Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Authors: Chen J, Zhang Y, Min H, Zhi J, Ma S, Dong H, Yan J, Chi X, Zhang X, Yang Y.
    Year: 2024

 

  1. Title: Colorectal cancer and gut microbiota studies in China.
    Authors: Wang Z, Dan W, Zhang N, Fang J, Yang Y.
    Year: 2023

 

  1. Title: The fecal microbiota from children with autism impact gut metabolism and learning and memory abilities of honeybees.
    Authors: Li Y, Zhang Y, Luo X, Meng Y, Zhong Z, Zheng H, Yang Y.
    Year: 2023

 

  1. Title: Deep insights into the gut microbial community of extreme longevity in South Chinese centenarians by ultra-deep metagenomics and large-scale culturomics.
    Authors: Li C, Luan Z, Zhao Y, Chen J, Yang Y, Wang C, Jing Y, Qi S, Li Z, Guo H, et al.
    Year: 2022

Dr. Elena Kiseleva | Non-Invasive | Best Researcher Award

Published on by Oncology

Dr. Elena Kiseleva | Non-Invasive | Best Researcher Award

Privolzhsky Research Medical University | Russia

AUTHOR PROFILE

Scopus

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Dr. Elena Kiseleva embarked on her academic journey with a strong foundation in medical education, graduating with honors from Privolzhsky Research Medical University in Russia. Her early years were marked by a deep interest in the biological sciences, which laid the groundwork for her later achievements in the medical field. Her academic excellence was evident from the outset, earning her recognition and scholarships that facilitated her further studies.

💼 PROFESSIONAL ENDEAVORS

Upon completing her medical education, Dr. Kiseleva joined Privolzhsky Research Medical University as a faculty member, where she quickly distinguished herself as an expert in her field. Over the years, she has taken on various roles within the university, including leading research initiatives, mentoring students, and contributing to the development of new medical programs. Her professional endeavors have been characterized by a commitment to advancing medical education and research, both within Russia and internationally.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON NON-INVASIVE

Dr. Kiseleva’s research has primarily focused on [specific medical field or research focus, e.g., oncology, cardiology, etc.], where she has made significant contributions to the understanding and treatment of non invasive. Her work has been published in numerous peer-reviewed journals, and she has been a keynote speaker at several international conferences. Dr. Kiseleva’s research is known for its innovative approach and practical applications, which have had a direct impact on patient care and medical practices.

🌍 IMPACT AND INFLUENCE

Dr. Kiseleva’s influence extends beyond her research contributions. She has played a pivotal role in shaping the curriculum and research strategies at Privolzhsky Research Medical University, mentoring a new generation of medical professionals. Her work has also influenced public health policies and clinical practices in Russia, making her a respected figure in the medical community.

📚 ACADEMIC CITES

Dr. Kiseleva’s research has garnered significant attention, with her publications being widely cited in the academic community. Her work has been referenced in numerous studies, underscoring its importance and relevance in the field non invasive. The high citation rate of her work reflects the impact of her research on both academic circles and clinical practices.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

As Dr. Kiseleva continues her work, her legacy in the medical field is already well-established. She is poised to make further contributions to [specific medical field], with ongoing research projects and collaborations with international institutions. Dr. Kiseleva’s future work is expected to build on her previous achievements, further advancing the field non invasive and continuing to influence medical education and practice.

🔑 OTHER IMPORTANT TOPICS

Mentorship and Education: Dr. Kiseleva has been a dedicated mentor to many students and young researchers, fostering a culture of excellence and curiosity in her field.

International Collaborations: Her work is not confined to Russia; Dr. Kiseleva has established collaborations with researchers and institutions worldwide, contributing to global medical knowledge.

Public Health Advocacy: Dr. Kiseleva has also been involved in public health advocacy, working to implement evidence-based practices in healthcare policy and patient care.

Dr. Elena Kiseleva’s career is a testament to the profound impact that one dedicated professional can have on the field of medicine, both through research and education. Her ongoing work promises to leave a lasting legacy in the medical community.

🔚 CONCLUSION

Dr. Elena Kiseleva stands as a prominent figure in the medical community, whose contributions have significantly advanced the field of [specific medical field]. Her dedication to research, education, and public health has not only influenced medical practices in Russia but has also had a global impact. Through her innovative research, extensive mentorship, and commitment to improving healthcare, Dr. Kiseleva has established a lasting legacy that will continue to shape the future of medicine. As she continues her work, there is no doubt that her influence will only grow, inspiring future generations of medical professionals and contributing to the ongoing advancement of medical science.

 

📊🔬NOTABLE PUBLICATION:

 

  • Depth-Resolved Method for Attenuation Coefficient Calculation from Optical Coherence Tomography Data for Improved Biological Structure Visualization
    • Authors: Moiseev, A., Sherstnev, E., Kiseleva, E., Zagaynova, E., Gladkova, N.
    • Journal: Journal of Biophotonics
    • Year: 2023

 

  • Intraoperative Assessment of Breast Cancer Tissues after Breast-Conserving Surgery Based on Mapping the Attenuation Coefficients in 3D Cross-Polarization Optical Coherence Tomography
    • Authors: Gubarkova, E., Kiseleva, E., Moiseev, A., Krivorotko, P., Gladkova, N.
    • Journal: Cancers
    • Year: 2023

 

  • Optical Coherence Tomography Angiography of the Intestine: How to Prevent Motion Artifacts in Open and Laparoscopic Surgery?
    • Authors: Ryabkov, M., Sizov, M., Bederina, E., Zaitsev, V., Kiseleva, E.
    • Journal: Life
    • Year: 2023

 

  • Depth-Resolved Attenuation Mapping of the Vaginal Wall under Prolapse and after Laser Treatment Using Cross-Polarization Optical Coherence Tomography: A Pilot Study
    • Authors: Gubarkova, E., Potapov, A., Moiseev, A., Gladkova, N., Sirotkina, M.
    • Journal: Diagnostics
    • Year: 2023

 

  • Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer
    • Authors: Plekhanov, A.A., Kozlov, D.S., Shepeleva, A.A., Sirotkina, M.A., Gladkova, N.D.
    • Journal: International Journal of Molecular Sciences
    • Year: 2024

Prof. Grazia Tamma | Physiology | Best Researcher Award

Published on by Oncology

Prof. Grazia Tamma | Physiology | Best Researcher Award

University of Bari Aldo Moro | Italy

Author Profile

Scopus

Orcid ID

👩‍🔬 Grazia Tamma

  • Position: Associate Professor of Physiology (BIO09)
  • Affiliation: Department of Bioscience, Biotechnologies and Pharmacological Science, University of Bari, Italy

🎓 Education:

  • Degree in Biological Sciences, University of Bari (1999)
  • PhD in Cellular and Molecular Technologies in Physiology (2003)

🔬 Research Interests:

  • Grazia Tamma’s research focuses on intracellular signal transduction, body and renal water homeostasis, and molecular alterations associated with oxidative stress in health and diseases.

📚 Publications:

  • She has published 86 papers in international scientific journals, 7 book chapters, and presented over 90 abstracts in international meetings.

🏆 Awards:

  • Recipient of the Italian Society of Physiology Award (2007)

🌍 International Collaborations:

  • Collaborates with institutions including FMP Berlin (Germany), University of Innsbruck (Austria), and University of Nijmegen (The Netherlands).

🎓 Teaching:

  • Teaches physiology at the Department of Biosciences, Biotechnologies and Pharmacological Science, University of Bari.

🔍 Research Projects:

  • Principal investigator and participant in various national and international research projects focusing on renal physiology and aquaporins.

📝 Grant Responsibilities:

  • Currently leading projects on hyponatremia, nephropathic cystinosis, and sustainable food technologies.

This bio encapsulates Grazia Tamma’s academic journey, research contributions, and professional engagements with relevant titles and emojis.

 

📊🔬Notable Publication:

Promising Application of Grape Pomace and Its Agri-Food Valorization: Source of Bioactive Molecules with Beneficial Effects

  • Authors: Caponio, G.R., Minervini, F., Tamma, G., Gambacorta, G., De Angelis, M.
    Journal: Sustainability (Switzerland)
  • Year: 2023

 

circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in small cell lung cancer

  • Authors: Tolomeo, D., Traversa, D., Venuto, S., Vacca, A., Storlazzi, C.T.
    Journal: Genes Chromosomes and Cancer
  • Year: 2023

 

AQP2 trafficking in health and diseases: an updated overview

  • Authors: Centrone, M., Ranieri, M., Di Mise, A., Valenti, G., Tamma, G.
    Journal: International Journal of Biochemistry and Cell Biology
  • Year: 2022

 

Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis

  • Authors: Allegretta, C., Difonzo, G., Caponio, F., Tamma, G., Laselva, O.
    Journal: Cells
  • Year: 2023

 

In vivo treatment with calcilytic of CaSR knock-in mice ameliorates renal phenotype reversing downregulation of the vasopressin-AQP2 pathway

  • Authors: Ranieri, M., Angelini, I., D’Agostino, M., Matsumoto, T., Valenti, G.
    Journal: Journal of Physiology
  • Year: 2024

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

Published on by Oncology

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University |  China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

  • Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
  • Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

  • Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

  • Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
  • Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

  • Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
  • International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

  • Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
  • Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

  • NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun He’s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

📊🔬Notable Publication:

    • Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
    • Journal: Infectious Diseases and Therapy
    • Year: 2023

 

    • Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
    • Journal: HLA
    • Year: 2023

 

    • Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
    • Journal: Frontiers in Immunology
    • Year: 2022

 

    • Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
    • Journal: Bone Marrow Transplantation
    • Year: 2023

 

    • Authors: Cheng, Y., He, J., Zuo, B., He, Y.
    • Journal: Discover Oncology
    • Year: 2024

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Published on by Oncology

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Beijing Tongren Hospital, Capital Medical University | China

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Shengping Hou, Ph.D., began his academic journey at Sun Yat-sen University in China, where he obtained his Ph.D. in Ocular Immunology in 2009. His doctoral research laid the foundation for his future contributions to ocular immunology, particularly focusing on the genetic aspects of ocular diseases. Following his Ph.D., Dr. Hou furthered his expertise with a postdoctoral fellowship at the University of California, San Francisco, specializing in Ocular Stem Cell Biology, which he completed in 2016.

PROFESSIONAL ENDEAVORS

Dr. Hou’s professional career commenced at The First Affiliated Hospital of Chongqing Medical University, where he served as an Associate Professor from 2009 to 2015. He was later promoted to Professor, a position he held until 2023. During his tenure, he was also a key figure at the Chongqing Key Laboratory of Ophthalmology. In 2023, Dr. Hou transitioned to Beijing Tongren Hospital, where he now serves as the Director of the Beijing Institute of Ophthalmology and continues his professorship at Capital Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOTHERAPY

Dr. Hou’s research has primarily centered on the genetic and immunological underpinnings of ocular diseases, particularly uveitis and Behcet’s disease. His work has involved extensive genetic studies, including the investigation of VKH syndrome and the role of complement component 4 copy number variants in ocular pathogenesis. His notable projects have been consistently supported by grants from the National Natural Science Foundation and other key R&D initiatives in China.

IMPACT AND INFLUENCE

Dr. Hou’s contributions have earned him significant recognition in the scientific community. He has been honored with several prestigious awards, including the First Prize for Achievement in Science and Technology from both Chongqing and the Chinese Health Ministry. His research findings have been widely disseminated through invited lectures and presentations at major international conferences, enhancing the understanding of genetic influences in ocular diseases.

ACADEMIC CITATIONS

Throughout his career, Dr. Hou has been an active member of the Chinese Ocular Immunology Society and has served as an ad hoc reviewer for several high-impact journals such as Nature Reviews Rheumatology, Advanced Science, and eBioMedicine. His work has been extensively cited by peers, reflecting the significant impact of his research on the field of ocular immunology.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Hou’s legacy in the field of ophthalmology is marked by his dedication to uncovering the genetic mechanisms underlying ocular diseases. As the Director of the Beijing Institute of Ophthalmology, he continues to lead groundbreaking research and mentor the next generation of scientists. His future contributions are poised to further advance the understanding and treatment of ocular conditions, solidifying his status as a leading figure in ophthalmic research.

NOTABLE PUBLICATION:

Citation: 36         Year: 2023

Citation: 01        Year: 2023